HIV-related severe thrombocytopenia in intravenous drug users: prevalence, response to therapy in a medium-term follow-up, and pathogenetic evaluation

AIDS. 1990 Jan;4(1):29-34.

Abstract

Severe thrombocytopenia (TP) accounted for 5.3% of cases in a consecutive series of 380 HIV-infected intravenous drug users (IVDUs) at presentation. Forty-one of 53 subjects with severe TP showed haemorrhages and were treated as follows: ten were splenectomized, 17 were given high-dose intravenous immunoglobulins (HDIg), and 10 received anti-Rh(D) immunoglobulins (anti-Rh Ig). Splenectomy induced a complete clinical response in all cases: four out of 10 patients maintained platelet counts greater than 100 x 10(9)/l. HDlg gave a good clinical response in all patients, but eight out of 17 suffered haemorrhages during the follow-up and recall treatments were necessary. Six out of 10 patients treated with anti-Rh lg maintained platelet counts greater than 30 x 10(9)/l, but in two cases the treatment was interrupted because of severe haemolysis. No patient progressed to overt AIDS during the follow-up. Splenectomized patients in particular did not show adjunctive risks of worsening of the HIV-related clinical picture. A platelet kinetic study performed in 20 patients with severe HIV-related TP suggests a possible role for platelet sequestration in TP of HIV-infected IVDUs, in which a liver involvement is very frequent.

MeSH terms

  • Adult
  • Female
  • Follow-Up Studies
  • HIV Infections / complications*
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunoglobulin G / therapeutic use*
  • Immunoglobulins / administration & dosage*
  • Infusions, Intravenous
  • Male
  • Platelet Count
  • Prevalence
  • Rho(D) Immune Globulin
  • Splenectomy
  • Substance Abuse, Intravenous / complications*
  • Thrombocytopenia / blood
  • Thrombocytopenia / epidemiology
  • Thrombocytopenia / etiology*
  • Thrombocytopenia / therapy*

Substances

  • Immunoglobulin G
  • Immunoglobulins
  • Rho(D) Immune Globulin